Scynexis Inc(SCYX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.84 | Insider Own | 3.91% | Shs Outstand | 9.9M | Perf Week | -9.96% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 20.45% | Insider Trans | - | Shs Float | 9.6M | Perf Month | -2.79% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.72 | Inst Own | 56.18% | Short Float | 4.37% | Perf Quarter | 13.25% |
| Income | -0.01B | P/S | 2.43 | EPS this Y | -113.97% | Inst Trans | 12.8% | Short Ratio | 3.06 | Perf Half Y | -34.14% |
| Sales | 0.02B | P/B | 0.7 | EPS next 5Y | -15.4% | ROA | -15.09% | Short Interest | 0.42M | Perf YTD | -7.1% |
| Book/sh | 6.73 | P/C | 0.86 | EPS past 3/5Y | 51.09% 49.3% | ROE | -18.38% | 52W High | -55.15% ($10.48) | Perf Year | -43.51% |
| Cash/sh | 5.44 | P/FCF | - | Sales past 3/5Y | 59.35% - | ROIC | -14.97% | 52W Low | 33.14% ($3.53) | Perf 3Y | -82.3% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 45.39% | Gross Margin | - | Volatility(W/M) | 5.43% 6.97% | Perf 5Y | -91.3% |
| Dividend TTM | - | EV/Sales | -0.28 | Sales Y/Y TTM | 489.78% | Oper. Margin | -117.61% | ATR (14) | 0.35 | Perf 10Y | -98.12% |
| Dividend Ex-Date | - | Quick Ratio | 9.56 | EPS Q/Q | 156.51% | Profit Margin | -53.27% | RSI (14) | 41.23 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.56 | Sales Q/Q | -82.77% | SMA20 | -9.66% ($5.2) | Beta | 1.06 | Target Price | $36.55 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/10 | SMA50 | -1.54% ($4.77) | Rel Volume | 0.35 | Prev Close | $4.91 |
| Employees | 18 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | 224.33% 192.65% | SMA200 | -17.51% ($5.7) | Avg Volume(3M) | 0.14M | Price | $4.7 |
| IPO | 2014/5/2 | Option/Short | Yes/Yes | Trades | 478 | Volume | 47,362 | Change | -4.28% |
Company
SCYX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This is a US biotech developing innovative antifungal agents to treat drug-resistant fungal infections. Its FDA-approved antifungal BREXAFEMME® (ibrexafungerp) is used to treat vulvovaginal candidiasis, and the company has licensed it out to GSK to drive global development and commercialization. It is also developing a next-generation antifungal pipeline candidate, SCY-247.
Over the past 1 year, on the lower side
55% below its 1-year high.
SCYX has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -114.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -82.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 56.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VTI 0.00%
VXF 0.00%
BSVO -It ranks #4 in the industry
Based on market cap of $47M.
SCYX $47M PER -
TAK $58B PER -
TEVA $42B PER 61.1
HLN $41B PER 19.0
FAQ
What kind of company is SCYX?
SCYX belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SCYX?
The market cap of SCYX is approximately $47M, ranking 4,974 within its sector.
What is the 52-week high and low for SCYX?
SCYX has recorded a 52-week high of $10.48 and a low of $3.53.
